Paper88606
Combined management of malignant teratoma of the testis.
Peckham MJ and 3 others. Lancet, 1979. Cited by 248 papers, by iCite.
Cite this record
ConductScience Library. Combined management of malignant teratoma of the testis. Papers, record 88606. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/88606
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bleomycin | Major topic |
| Cisplatin | Major topic |
| Teratoma | Major topic |
| Testicular Neoplasms | Major topic |
| Vinblastine | Major topic |
| Abdominal Neoplasms | |
| Drug Therapy, Combination | |
| Humans | |
| Lung Neoplasms | |
| Male | |
| Neoplasm Metastasis |
Source PubMed
Cited by46
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 248 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37088800 | Risk and mortality of testicular cancer in patients with neurodevelopmental or other psychiatric disorders. | Br J Cancer | 2023 | https://conductscience.org/library/papers/37088800 | PubMed |
| 34667955 | Thromboembolic Events During Treatment with Cisplatin-based Chemotherapy in Metastatic Testicular Germ-cell Cancer 2000-2014: A Population-based Cohort Study. | Eur Urol Open Sci | 2021 | https://conductscience.org/library/papers/34667955 | PubMed |
| 34341387 | Serum miR371 in testicular germ cell cancer before and after orchiectomy, assessed by digital-droplet PCR in a prospective study. | Sci Rep | 2021 | https://conductscience.org/library/papers/34341387 | PubMed |
| 26834905 | Multiple secondary malignancies following radiation therapy for testicular cancer. | Can Urol Assoc J | 2015 | https://conductscience.org/library/papers/26834905 | PubMed |
| 23921754 | Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. | Nat Med | 2013 | https://conductscience.org/library/papers/23921754 | PubMed |
| 23169336 | Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancer. | Br J Cancer | 2012 | https://conductscience.org/library/papers/23169336 | PubMed |
| 22294556 | The safety of embryonic stem cell therapy relies on teratoma removal. | Oncotarget | 2012 | https://conductscience.org/library/papers/22294556 | PubMed |
| 22184390 | Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/22184390 | PubMed |
| 19940282 | Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. | J Natl Cancer Inst | 2009 | https://conductscience.org/library/papers/19940282 | PubMed |
| 19513721 | Good-risk-advanced germ cell tumors: historical perspective and current standards of care. | World J Urol | 2009 | https://conductscience.org/library/papers/19513721 | PubMed |
| 18792787 | Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. | J Cancer Surviv | 2008 | https://conductscience.org/library/papers/18792787 | PubMed |
| 17634758 | Epidemiology and treatment delay in testicular cancer patients: a retrospective study. | Int Urol Nephrol | 2008 | https://conductscience.org/library/papers/17634758 | PubMed |
| 17262080 | Mortality and incidence of second cancers following treatment for testicular cancer. | Br J Cancer | 2007 | https://conductscience.org/library/papers/17262080 | PubMed |
| 12644825 | Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours. | Br J Cancer | 2003 | https://conductscience.org/library/papers/12644825 | PubMed |
| 11104556 | A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party. | Br J Cancer | 2000 | https://conductscience.org/library/papers/11104556 | PubMed |
| 10672958 | Factors involved in diagnostic delay of testicular cancer. | Int Urol Nephrol | 1999 | https://conductscience.org/library/papers/10672958 | PubMed |
| 8826863 | Treatment of advanced seminoma with cyclophosphamide, vincristine and carboplatin on an outpatient basis. | Br J Cancer | 1996 | https://conductscience.org/library/papers/8826863 | PubMed |
| 8586515 | Management of testicular cancer with combined-modality treatment. | Int Urol Nephrol | 1995 | https://conductscience.org/library/papers/8586515 | PubMed |
| 8439506 | Clinical profile and problems of management of 108 cases of germ cell tumours of testis at Institute Rotary Cancer Hospital, All India Institute of Medical Sciences New Delhi 1985-1990. | Br J Cancer | 1993 | https://conductscience.org/library/papers/8439506 | PubMed |
| 7880748 | Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group. | Br J Cancer | 1995 | https://conductscience.org/library/papers/7880748 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/88606
GET https://conductscience.org/api/papers/v1/88606/cited_by?page=2